Drugs / XL228
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00526838 | Sep 2007 → Dec 2010 | cancer, lymphoma | Exelixis | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00464113 | May 2007 → Dec 2010 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), chronic myeloid leukemia | Exelixis | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-05-30 | Exelixis | Results Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases exelixis.com ↗
Exelixis, Inc. (Nasdaq: EXEL) today reported encouraging data from an ongoing Phase 1 dose-escalation trial of XL228 in patients with advanced malignancies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-05-30 | Exelixis | Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases exelixis.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00464113 ↗ |
| Known as | Exel-2280 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545085 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase ABL inhibitor” CHEMBL3545085 ↗1“BCR-ABL inhibitor” NCT00464113 ↗ |
| Modality | Small molecule | — CHEMBL3545085 ↗ |
| Route | Intravenous | “1-hour IV infusion” NCT00464113 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL3545085 ↗ |
| Target | IGF1R | “multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl)” NCT00526838 ↗ |
| Target | SRC | “multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl)” NCT00526838 ↗ |